Pre-operative Carboplatin/Paclitaxel Versus 5-Fluorouracil (5-FU)-based Chemoradiotherapy for Older Adults With Esophageal Cancer.

Autor:	Al-Jumayli M; Department of Medicine, Division of Medical Oncology, Kansas University Cancer Center, Kansas City, KS, U.S.A.; Department of Medicine, Division of Hematology/Oncology, South Florida University/Moffit Cancer Center, Tampa, FL, U.S.A., Choucair K; Department of Medicine, Kansas University School of Medicine, Wichita, KS, U.S.A., Al-Obaidi A; Department of Medicine, Division of Hematology/Oncology, University of Missouri-Kansas City, Kansas City, MO, U.S.A., Park R; MetroWest Medical Center/Tufts University School of Medicine, Framingham, MA, U.S.A., Bansal A; Department of Medicine, Division of Gastroenterology and Hepatology, University of Kansas Medical Center and Kansas Cancer Institute, Kansas City, KS, U.S.A., Baranda J; Department of Medicine, Division of Medical Oncology, Kansas University Cancer Center, Kansas City, KS, U.S.A., Sun W; Department of Medicine, Division of Medical Oncology, Kansas University Cancer Center, Kansas City, KS, U.S.A., Saeed A; Department of Medicine, Division of Medical Oncology, Kansas University Cancer Center, Kansas City, KS, U.S.A. asaeed@kumc.edu.
Jazyk:	angličtina
Zdroj:	Anticancer research [Anticancer Res] 2022 Jan; Vol. 42 (1), pp. 59-66.
DOI:	10.21873/anticanres.15457
Abstrakt:	Background/aim: This study aimed to compare the efficacy and tolerability of pre-operative platinum/5-fluorouracil (P5F) and carboplatin/paclitaxel (CP), in combination with radiation therapy in older adults with locally advanced, stage I-III esophageal cancer. Patients and Methods: We retrospectively reviewed 51 patients aged ≥70 years who underwent chemoradiotherapy followed by esophagectomy for stage I-III esophageal cancer between 2008 and 2018. Pathological complete response (pCR) and survival rates were compared across the two chemotherapy regimen arms. Results: Treatment completion (p=0.28), pCR (p=0.89), and partial response rates were similar across both chemotherapy groups. Overall survival (OS) and disease-free survival (DFS) were similar across both groups with HR=0.80 (p=0.62) and HR=0.72 (p=0.72) respectively. Conclusion: The lesser toxic CP regimen may be used in older patients with locally advanced esophageal cancer, with tumor response and survival rates similar to P5F chemotherapy. (Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu